Johnson & Johnson (NYSE:JNJ) Trading 0.3% Higher

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.3% during mid-day trading on Monday . The company traded as high as $146.43 and last traded at $146.03. 1,125,545 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 7,321,098 shares. The stock had previously closed at $145.54.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Bank of America lowered their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Royal Bank of Canada restated an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research report on Monday. Finally, The Goldman Sachs Group started coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a “neutral” rating and a $160.00 target price for the company. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $174.07.

Johnson & Johnson Trading Up 0.0 %

The stock has a market cap of $350.32 billion, a price-to-earnings ratio of 9.10, a P/E/G ratio of 2.42 and a beta of 0.53. The business has a 50-day simple moving average of $148.38 and a two-hundred day simple moving average of $154.71. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. Johnson & Johnson’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.68 EPS. Equities analysts forecast that Johnson & Johnson will post 10.63 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors have recently made changes to their positions in JNJ. WealthPlan Investment Management LLC raised its holdings in shares of Johnson & Johnson by 495.4% during the 3rd quarter. WealthPlan Investment Management LLC now owns 67,728 shares of the company’s stock worth $10,549,000 after buying an additional 56,352 shares in the last quarter. King Wealth lifted its holdings in shares of Johnson & Johnson by 0.7% in the third quarter. King Wealth now owns 53,426 shares of the company’s stock worth $8,321,000 after acquiring an additional 383 shares during the last quarter. Hardy Reed LLC boosted its stake in shares of Johnson & Johnson by 7.0% in the 3rd quarter. Hardy Reed LLC now owns 5,637 shares of the company’s stock valued at $878,000 after purchasing an additional 368 shares in the last quarter. Capstone Wealth Management Group LLC grew its holdings in shares of Johnson & Johnson by 2.1% during the 3rd quarter. Capstone Wealth Management Group LLC now owns 6,811 shares of the company’s stock valued at $1,061,000 after purchasing an additional 138 shares during the last quarter. Finally, Kensington Investment Counsel LLC increased its position in Johnson & Johnson by 5.6% during the 3rd quarter. Kensington Investment Counsel LLC now owns 18,652 shares of the company’s stock worth $2,905,000 after purchasing an additional 996 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.